Estrogen receptor-alpha, breast cancer patients and tamoxifen response

	Tweet

Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute.

Approximately 50% of breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that ER-alpha S118-P is required for response to tamoxifen.

Göran Landberg, M.D., Ph.D., of the Breakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology at the University of Manchester, and colleagues evaluated data from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs. no systemic treatment. The association between recurrence-free survival and ER-alpha S118-P expression in tumor tissue was investigated.

Researchers found evidence of a statistically significant recurrence-free survival benefit from adjuvant tamoxifen, compared with no systemic treatment, among patients whose tumors had high ER-alpha S118-P expression (23.7 vs. 72.2 recurrences per 1000 person-years) but not among patients whose tumors had low expression (51.0 vs. 57.0 recurrences per 1000 person-years). ER-alpha S118-P was not associated with a benefit among untreated patients.

“Our study highlights the importance of assessing the functionality of a drug target,” the authors write. “Future studies are necessary to evaluate whether ER-alpha S118-P expression is associated with tamoxifen response among post-menopausal patients.”

###

Contact: Göran Landberg, , +4640331953 (Sweden)

Note to Reporters: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Visit JNCI online at http://jnci.oxfordjournals.org and the JNCI press room at http://www.oxfordjournals.org/our_journals/jnci/press_room.html

For the latest cancer news and studies, follow us on Twitter @JNCI_Now

Contact: Steve Graff

301-841-1285
Journal of the National Cancer Institute

RELATED STORIES:
Breast MRI spots other cancers, may alter treatment plan   Research on Tamoxifen Leads to Recommendation for CYP2D6 Gene Test   The most aggressive forms of breast cancer elude the cellular control mechanisms in order to expand   Breast cancer incidence is lower for Latinas   New Insight into the Biology of the BRCA1 Breast Cancer Gene   Nimesulide fights breast cancer by targeting key enzyme   Racial Differences in Breast Cancer Treatment Persist, Despite Similar Economics   Manchester researchers announce new methods of beating breast cancer   Not all women change lifestyle after cancer   Ovarian cysts linked to lower breast cancer risk   3-D doppler ultrasound helps identify breast cancer   New tool predicts women’s outcome in breast cancer   Error rate higher in breast imaging reports generated by automatic speech recognition   Researchers Identify Gene That Regulates Breast Cancer Metastasis   Adolescent alcohol consumption and breast cancer   Partners of breast cancer patients are at risk of developing mood disorders   Breast Cancer and the Environment   ‘Microtentacles’ on tumor cells appear to play role in how breast cancer spreads   In Flurry of Studies, Researcher Details Role of Apples in Inhibiting Breast Cancer   Device May Customize Radiation Therapy, Reduce Treatment Time   Singling out the real breast cancer among the lumps   Hair straightening chemicals not linked to breast cancer risk in African-Americans

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]